Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LOWER: Lomitapide Observational Worldwide Evaluation Registry

Next Previous
Trial Profile

LOWER: Lomitapide Observational Worldwide Evaluation Registry

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lomitapide (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions
  • Acronyms LOWER
  • Sponsors Aegerion Pharmaceuticals; Amryt Pharma

    • Most Recent Events

    • 01 Feb 2023 Results assessing long-term hepatic safety of lomitapide from phase III clinical studies and extension study: NCT00730236, NCT00943306 and NCT02135705 published in the Liver International
    • 30 Mar 2020 Results (n=187; as of 1 Mar 2019) presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology.
    • 14 Nov 2018 Results of analysis using a published model of life expectancy and time to first MACE, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top